Pfizer’s EPS Has Fallen 65% From Its Peak, Here’s Why That Might Be the Point
Pfizer is navigating the post-COVID earnings hangover, and the question is whether the underlying business is strong enough to matter.
Read the full articleYou might also wanna read
How COVID-19 Has Impacted Tech Earnings
Cloud firms rise to the top of tech pile as reports roll in. It could be a false positive.
Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue
NEW YORK, July 15, 2026, 17:09 EDT Pfizer Inc. (NYSE:PFE) shares rose 2.35% to $24.82 on Wednesday after Sanofi SA (NASDAQ:SNY) brought a ne
Opinion: Pfizer's Dividend Is Riskier Than You Might Think
A 7% dividend yield will grab your attention, but be sure to read the fine print.
Pfizer (NYSE:PFE) scores FDA approval but Wall Street reaction muted
New York, July 12, 2026, 17:19 (EDT) U.S. markets are shut for the weekend, so investors are waiting to see if Friday’s FDA approval of Padc
This Stock Stumbled Last Year. Now It's the First Half's Best Performing Mega-Cap Healthcare Stock. Is It Too Late to Buy?
This company's recovery efforts are bearing fruit.
Kyverna Therapeutics Sinks 13%: Here’s Why
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the qu
Comments
Sign in to join the conversation.
No comments yet. Be the first.